Betrixa 40

Indications

BetriXa is prescribed for the prevention of venous thromboembolism (VTE) in adults hospitalized for acute medical conditions, particularly those with limited mobility and other VTE risk factors.

Pharmacology

Betrixaban, a factor Xa inhibitor, selectively targets the active site of factor Xa, reducing thrombin generation without impacting platelet aggregation.

Dosage & Administration

The recommended regimen involves an initial single dose of 160 mg, followed by 80 mg once daily, taken consistently with food for 35 to 42 days.

Interaction

Medications that inhibit or induce P-glycoprotein (P-gp) may alter BetriXa blood levels, while anticoagulants, antiplatelets, and thrombolytics may heighten bleeding risks.

Contraindications

Avoid Betrixaban in patients with active pathological bleeding or severe hypersensitivity reactions.

Side Effects

Bleeding is the most common adverse reaction, with a potential risk of epidural or spinal hematoma during anesthesia.

Pregnancy & Lactation

Betrixaban’s use during pregnancy may elevate hemorrhage risk. Data on its presence in human milk and effects on breastfeeding infants are unavailable.

Precautions & Warnings

Carefully monitor for signs of bleeding and exercise caution during neuraxial anesthesia or puncture. Adjust dosage in patients with renal impairment and avoid BetriXa in those with moderate to severe hepatic impairment.

Use in Special Populations

Patients with severe renal impairment may require dosage adjustments, while those with moderate to severe hepatic impairment should avoid BetriXa.

Therapeutic Class

BetriXa falls under the category of antiplatelet drugs.

Storage Conditions

Store BetriXa below 30°C, protected from light and moisture, and keep it out of children’s reach.